Jessica M. Gannon, MD, and Jessica Nichols, PharmD, discuss the specialty medications that are used to treat schizophrenia.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Discuss the importance of care continuity for long acting injectable antipsychotics and clozapine
- Name two or more specific threats to continued prescribing of clozapine and long-acting injectable antipsychotics (LAIAs) as presented by the COVID-19 pandemic
- Review specific strategies for continuing LAIAs and clozapine during a state of emergency
Disclosures
No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Accreditation Statement
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh designates enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
For your credit transcript, please access our website four weeks postcompletion at http://ccehs.upmc.com and follow the link to the Credit Transcript page.
Release Date: 2/18/2021 | Last Modified On: 2/24/2022 | Expires: 2/21/2023
